FDA Approves Neuralink’s Brain Chip for Second Participant

The U.S. Food and Drug Administration (FDA) has granted approval to Elon Musk’s Neuralink to proceed with implanting its brain chip in a second individual. This move comes after endorsing the company’s proposed remedies for issues encountered in the initial test subject.

Deeper Implantation of Ultrafine Wires Proposed

Neuralink’s solutions involve embedding certain ultrafine wires of the device deeper into the brain. This approach, according to sources familiar with the matter and documents reviewed by The Wall Street Journal, aims to address the challenges faced during the initial test.

Neuralink’s deep embedding of wires may enhance brain-computer interface efficiency, but poses potential risks, Barron’s Print Edition said.

Emotional Journey of Initial Participant Revealed

As Neuralink prepares for its next test subject, Noland Arbaugh, the primary participant, shares his emotional journey. From the excitement of newfound capabilities to the despair of functionality loss, Arbaugh reflects on the impact of the device on his life.

Initial Success Followed by Setback

Arbaugh, a quadriplegic, experienced remarkable improvements in communication and interaction following the implantation. However, a decline in the device’s efficacy a month later plunged him into despair, highlighting the challenges of pioneering neural technology.

Neuralink’s Response and Future Plans

Neuralink informed Arbaugh that despite challenges, around 15% of the implanted threads remain intact. With FDA approval, the company is set to implant its device in a second participant soon, aiming to study and enhance its functionality.

Overcoming Challenges and Gaining Insights

Despite setbacks, Neuralink’s engineers have made significant strides in improving device performance. By refining signal interpretation algorithms, they have restored functionality and provided hope for future advancements in neural technology.

Looking Ahead

Neuralink remains committed to its mission, aiming to implant its device in 10 individuals this year. Plans to expand trials internationally underscore the company’s dedication to advancing neurotechnology.

Diversity and Accessibility

Neuralink acknowledges the importance of diversity in its trials and aims to include a diverse range of participants. Efforts to ensure accessibility extend to international expansion and patient registry availability.

Arbaugh’s Optimism and Contribution

Arbaugh’s journey, though marked by challenges, serves as inspiration for future participants and advancements in neural technology. His resilience and optimism reflect the potential for transformative change in the field.

Neuralink’s journey continues, guided by the mission to revolutionize human-computer interaction and improve the lives of individuals with neurological conditions.

Get a 77% discount on a 2-year digital news bundle: Financial Times and The New York Times. Enjoy unlimited access to NYTimes news, cooking, crossword, The Economist Epaper, and insights from economists like Paul Krugman and Joseph Stiglitz. Stay globally informed with Financial Times’ “Premium Subscription.” Subscribe now!